- Creative Medical Technology Holdings (CELZ) has evolved from proof-of-concept to clinical trials in 2025, leveraging its proprietary cellular platforms **AlloStem, ImmCelz, and iPScelz** for regenerative stem cell therapies.  **[1187953_0eee9780642d4bf6a1a2bdf94ab28ac6_0]** 
- The company is advancing two FDA-cleared clinical programs: **CELZ-201-DDT (ADAPT Trial)** for chronic lower back pain, with topline results anticipated in the **first half of 2026**, and **CELZ-201 (CREATE-1 Trial)** for new-onset Type 1 Diabetes, with early data expected in **2026**.  **[1187953_0eee9780642d4bf6a1a2bdf94ab28ac6_1]**  These trials target markets estimated at approximately **$11 billion** and **$35 billion annually**, respectively.  **[1187953_0eee9780642d4bf6a1a2bdf94ab28ac6_1]** 
- Creative Medical strengthened its intellectual property in Q3 2025 by securing **two cornerstone U.S. patents** expanding ImmCelz coverage to Type 1 Diabetes (expires 2043) and Heart Failure (expires 2042), contributing to a portfolio of over **60 patents and pending applications**.  **[1187953_0eee9780642d4bf6a1a2bdf94ab28ac6_2]** 
- The company is integrating **Artificial Intelligence (AI)** into its iPScelz platform to accelerate target discovery, optimize donor cell selection, and simulate in vivo behavior, positioning itself in "Regenerative Medicine 2.0".  **[1187953_0eee9780642d4bf6a1a2bdf94ab28ac6_2]**

Creative Medical Technology Holdings Issues Shareholder Letter Highlighting Clinical Progress and IP Strength

- Creative Medical Technology Holdings (CELZ) highlighted the 2025 Nobel Prize in Physiology or Medicine awarded for discoveries in regulatory T cells (Tregs), noting that its **ImmCelz™ platform** is designed to harness this biology.  **[1187953_86cbba4792204bca8226de7610b0ff00_0]** 
- The company recently received **two U.S. Patents** for its proprietary ImmCelz™ platform: one for the prevention and/or treatment of **Type 1 Diabetes** (U.S. Patent Number 12931925B2, expires **2043-05-24**) and another for the treatment of **heart failure** and/or post-infarct pathological remodeling (U.S. Patent Number 12385011B2, expires **2042-12-15**).  **[1187953_86cbba4792204bca8226de7610b0ff00_0]** 
- CEO Timothy Warbington stated that these patents establish an **IP-fortified regenerative immunotherapy franchise** with a runway extending to at least **2042**, targeting significant market opportunities including over **five million** heart failure patients and **six million** refractory angina patients in the U.S..  **[1187953_86cbba4792204bca8226de7610b0ff00_0]** 
- The Type 1 diabetes program aligns with the company's ongoing **CREATE-1 clinical trial**.  **[1187953_86cbba4792204bca8226de7610b0ff00_0]**

CREATIVE MEDICAL TECHNOLOGY HOLDINGS (CELZ)